Partial Breast Irradiation in a Low-risk Population Screened With MRI

March 3, 2014 updated by: University of Chicago

Image Guided Partial Breast Irradiation (PBL) In A Low-Risk Population Screened With Magnetic Resonance Imaging (MRI)

This is a pilot study to determine if partial breast irradiation (PBI) limited to the region of the tumor bed following lumpectomy in patients screened with MRI provides historically similar rates of local failure, limited acute skin toxicity, late complications and cosmetic outcome when compared to patients treated with standard 3D-CRT to the whole breast.

Study Overview

Status

Withdrawn

Conditions

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60637
        • University of Chicago

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Stage 0 or I breast carcinoma
  • 40 years or older
  • Post menopausal
  • Lumpectomy with clear margins (>2mm)
  • Patients with invasive disease must have undergone an axillary staging by axillary dissection (with a minimum of 6 axillary nodes) or sentinal node biopsy
  • Gross disease must be unifocal with pathological tumor size 2cm or less
  • Target lumpectomy cavity must be clearly marked with surgical clips (the target lumpectomy cavity/whole breast reference volume must be <=30% based on the postoperative imaging)
  • Bilateral MRI of the breasts within previous 6 months of radiation therapy (RT) planning
  • If patient is eligible based on postoperative imaging, partial breast irradiation (PBI) is judged to be technically deliverable
  • Patients with a history of malignancies are eligible if they have stable disease as determined by their attending oncologist
  • Patient must have signed the consent form

Exclusion Criteria:

  • Men are not eligible
  • Patients with Stage II, II, or IV breast cancer
  • Pre- or peri-menopausal patients
  • Patients with positive lymph nodes
  • Patients with suspicious microcalcifications, densities, or palpable abnormalities unless biopsied and found to be benign
  • Patients with multifocal, multicentric, or bilateral breast cancer
  • Surgical margins that cannot be microscopically assessed or are positive at pathological evaluation
  • Patients with a history of breast cancer
  • Clear delineation of the extent of the target lumpectomy cavity is not possible
  • Breast implants (patients who have had implants removed are eligible)
  • Prior breast or thoracic RT for any condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rates of toxicity (breast edema/pain, hyperpigmentation, erythema) for patients receiving partial breast irradiation (PBI) compared to historical rates of toxicity of patients receiving whole breast irradiation (WBI)
Time Frame: During radiation therapy (5-10 days)
During radiation therapy (5-10 days)
Rates of toxicity (breast edema/pain, hyperpigmentation, erythema) for patients receiving PBI compared to historical rates of toxicity of patients receiving WBI
Time Frame: Post therapy (until death)
Post therapy (until death)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival Rates
Time Frame: 5 years
5 years
Cosmetic outcomes of breast PBI
Time Frame: 3 years
Comparison of cosmetic results (appearance, size, shape, texture, scaring) of breast treated with PBI to untreated breast.
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

May 1, 2012

Study Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

November 22, 2010

First Submitted That Met QC Criteria

December 6, 2010

First Posted (Estimate)

December 7, 2010

Study Record Updates

Last Update Posted (Estimate)

March 4, 2014

Last Update Submitted That Met QC Criteria

March 3, 2014

Last Verified

March 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • 09-025-A

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Partial Breast Irradiation

Subscribe